The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.
|Title of host publication||Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015|
|Publisher||American Institute of Physics Inc.|
|State||Published - 7 Jul 2016|
|Event||11th Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015 - Medellin, Colombia|
Duration: 30 Nov 2015 → 4 Dec 2015
|Name||AIP Conference Proceedings|
|Conference||11th Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015|
|Period||30/11/15 → 4/12/15|
Bibliographical notePublisher Copyright:
© 2016 Author(s).
- Radioablative Therapy
- Radiology Protection